CAI

Caris Life Sciences, Inc. Common Stock (CAI) | Rumor.io

Caris Life Sciences

CAI

Attention (50-day avg)0%

Attention rank (50-day avg)#908

Bullish sentiment (50-day avg)94%

Price to earnings ratio3.34

Market capitalization9B

Earnings per share9.58

Dividend yield (TTM)—

Revenue (annual)812M

Net income (annual)-68.1M

Social

What share of all stock conversation is about CAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 17

A Caris Life Sciences, Inc. ($CAI) trade on the 30th call option for September 26 with an entry price of $0.45 and a high-confidence setup.
The trade resulted in a 33% return with a price target by UBS and an IPO price breakout continuation.
The trade was executed with discipline and resulted in a 100% move from entry, with a clean return in less than one hour.

Generated by AI

Sentiment

Of the messages about CAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.78% -10.11	89.36% -2.64
Bearish	—	—	11.22% +10.11	10.64% +2.64

Bullish· Jan 2

$CAI's AI algorithms have a 99% success rate, making it a reliable choice for portfolio growth.
$CAI is poised for significant growth, with potential to reach 1000x minimum, driven by its dominance in the AI trading intelligence space.
$CAI's steady growth and lack of pump and dump nonsense make it a more attractive investment option for smart money.

Bearish· Jun 18

Caris Life Sciences, Inc. (CAI) is being acquired by Mitsubishi HC Capital for $56 per share in cash.
A put option for CAI with a break-even point of $54.16 is considered a "no brainer" by one investor.
CAI International has been downgraded from "Buy" to "Neutral" by B. Riley Securities analyst Liam Burke.

Generated by AI

Topics

Of the messages about CAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	14.49%
Technical Analysis	—	—	100%	28.46%
Earnings	—	—	0%	5.26%
Analysts	—	—	0%	21.92%
Macro	—	—	0%	29.87%
Controversies	—	—	0%	0%

Earnings· Jul 31

CAI International reports record revenue of $105.7 million and EPS of $0.97, beating estimates.
CAI International beats EPS estimates by $0.06 and beats on revenues, with EPS of $0.97 and revenue of $105.7 million.
CAI International misses Estimize EPS consensus by 7 cents, but beats Estimize Revenue consensus by $4.16 million, with EPS of 90 cents and revenue of $105.71 million.

Announcements· Jun 19

Caris Life Sciences, Inc. (CAI) was mentioned in a list of stocks to be interviewed on New To The Street / Newsmax TV on June 20, 2021.
Caris Life Sciences, Inc. (CAI) was included in a list of stocks to be discussed on a breaking news broadcast, but no specific announcement was made about the company.
No specific announcement was made about Caris Life Sciences, Inc. (CAI) in the provided news posts, as the company was mentioned in passing in multiple posts.

Technical Analysis· Apr 18

The stock price of Caris Life Sciences, Inc. (CAI) is being considered for a potential break above $22.5.
This implies a bullish sentiment for the stock, with a focus on its technical analysis.
The price level of $22.5 is being seen as a key resistance point for CAI.

Generated by AI

Community

Of the messages about CAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0.84%	3.4%	7.02%
Newcomers	—	99.16%	96.6%	92.98%

Regulars· Jun 18

The company behind CAI, Caris Life Sciences, Inc., has been sold to the owner of Beacon Intermodal Leasing, marking the end of CAI's life as an independent company.
The sale of CAI to its owner has been completed at a price of $56, a significant premium over its previous closing price.
The sale of CAI is seen as a strategic move by its owner, who has acquired the company for its assets and has managed to acquire it at a relatively low valuation, given its leverage and debt-to-equity ratio.

Newcomers· Sep 17

The newcomer is focused on the potential for a 33% return on investment in Caris Life Sciences, Inc. ($CAI) based on the stock's relative strength and IPO price breakout continuation.
The user is highlighting a "high-confidence" setup for a $30 call option on $CAI, with a target price of $0.90, representing a 100% move from the entry point of $0.45.
The newcomer is sharing a successful trade execution, achieving a 100% gain on $CAI in less than an hour, and expressing enthusiasm for continuing to share similar setups for others to consider.

Generated by AI

News

Caris Life Sciences SVP Denton sells $238,626 in shares

6d agoInvesting.com

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Caris Life Sciences has surged off its May low near 14. The molecular research firm for drug companies might turn profitable this year.

7d agoInvestor's Business Daily

Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)

8d agoSeeking Alpha

Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.

Key TakeawaysSector Rally: Caris Life Sciences (CAI) stock jumped 9. 61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.

12d agoYahoo Finance

Caris Life Sciences vice chairman Brille sells $12.1 million shares

12d agoInvesting.com

Caris Life Sciences: Diagnostics Growth With Room To Run (NASDAQ:CAI)

12d agoSeeking Alpha

Also Discussed

Investors talking about CAI also mention

#	Name	Attention
1	SSU - SIGNA Sports United N.V.	——
2	TGH - Textainer Group Holdings Limited	——
3	Avant USDAVUSD	0%new
4	ProShares Ultra Health Care ETFRXL	0.01%+0
5	CHN - The China Fund, Inc.	——
6	SPDR SSGA Global Allocation ETFGAL	0%0
7	GraniteShares Gold TrustBAR	0%0
8	Grupo Aeroportuario del Sureste S.A.B. de C.V. ADRASR	0%0
9	AECOMACM	0%new
10	White Mountains Insurance Group Ltd.WTM	0%0

Caris Life Sciences, Inc. Common Stock

Healthcare
Biotechnology

Caris Life Sciences, Inc. Common Stock is the equity of Caris Life Sciences, a precision medicine and diagnostics company focused on molecular profiling and anatomic pathology services. The company uses advanced molecular information and artificial intelligence to help support cancer detection, disease characterization, treatment selection, and recurrence monitoring. Its current portfolio includes tissue-based and blood-based testing solutions, alongside software-driven tools designed to integrate clinical and molecular data for healthcare providers. Caris Life Sciences serves medical practices, laboratories, researchers, and biopharmaceutical partners across the United States and international markets. Headquartered in Irving, Texas, Caris Life Sciences operates at the intersection of biotechnology, data analytics, and clinical diagnostics, making it an important participant in the healthcare technology market.

Website

Location

750 West John Carpenter Freeway

Irving, TX, 75039

United States

Social

What share of all stock conversation is about CAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 17

A Caris Life Sciences, Inc. ($CAI) trade on the 30th call option for September 26 with an entry price of $0.45 and a high-confidence setup.
The trade resulted in a 33% return with a price target by UBS and an IPO price breakout continuation.
The trade was executed with discipline and resulted in a 100% move from entry, with a clean return in less than one hour.

Generated by AI

Sentiment

Of the messages about CAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.78% -10.11	89.36% -2.64
Bearish	—	—	11.22% +10.11	10.64% +2.64

Bullish· Jan 2

$CAI's AI algorithms have a 99% success rate, making it a reliable choice for portfolio growth.
$CAI is poised for significant growth, with potential to reach 1000x minimum, driven by its dominance in the AI trading intelligence space.
$CAI's steady growth and lack of pump and dump nonsense make it a more attractive investment option for smart money.

Bearish· Jun 18

Caris Life Sciences, Inc. (CAI) is being acquired by Mitsubishi HC Capital for $56 per share in cash.
A put option for CAI with a break-even point of $54.16 is considered a "no brainer" by one investor.
CAI International has been downgraded from "Buy" to "Neutral" by B. Riley Securities analyst Liam Burke.

Generated by AI

Topics

Of the messages about CAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	14.49%
Technical Analysis	—	—	100%	28.46%
Earnings	—	—	0%	5.26%
Analysts	—	—	0%	21.92%
Macro	—	—	0%	29.87%
Controversies	—	—	0%	0%

Earnings· Jul 31

CAI International reports record revenue of $105.7 million and EPS of $0.97, beating estimates.
CAI International beats EPS estimates by $0.06 and beats on revenues, with EPS of $0.97 and revenue of $105.7 million.
CAI International misses Estimize EPS consensus by 7 cents, but beats Estimize Revenue consensus by $4.16 million, with EPS of 90 cents and revenue of $105.71 million.

Announcements· Jun 19

Caris Life Sciences, Inc. (CAI) was mentioned in a list of stocks to be interviewed on New To The Street / Newsmax TV on June 20, 2021.
Caris Life Sciences, Inc. (CAI) was included in a list of stocks to be discussed on a breaking news broadcast, but no specific announcement was made about the company.
No specific announcement was made about Caris Life Sciences, Inc. (CAI) in the provided news posts, as the company was mentioned in passing in multiple posts.

Technical Analysis· Apr 18

The stock price of Caris Life Sciences, Inc. (CAI) is being considered for a potential break above $22.5.
This implies a bullish sentiment for the stock, with a focus on its technical analysis.
The price level of $22.5 is being seen as a key resistance point for CAI.

Generated by AI

Community

Of the messages about CAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0.84%	3.4%	7.02%
Newcomers	—	99.16%	96.6%	92.98%

Regulars· Jun 18

The company behind CAI, Caris Life Sciences, Inc., has been sold to the owner of Beacon Intermodal Leasing, marking the end of CAI's life as an independent company.
The sale of CAI to its owner has been completed at a price of $56, a significant premium over its previous closing price.
The sale of CAI is seen as a strategic move by its owner, who has acquired the company for its assets and has managed to acquire it at a relatively low valuation, given its leverage and debt-to-equity ratio.

Newcomers· Sep 17

The newcomer is focused on the potential for a 33% return on investment in Caris Life Sciences, Inc. ($CAI) based on the stock's relative strength and IPO price breakout continuation.
The user is highlighting a "high-confidence" setup for a $30 call option on $CAI, with a target price of $0.90, representing a 100% move from the entry point of $0.45.
The newcomer is sharing a successful trade execution, achieving a 100% gain on $CAI in less than an hour, and expressing enthusiasm for continuing to share similar setups for others to consider.

Generated by AI

Caris Life Sciences

Social

Sep 17

Bullish· Jan 2

Bearish· Jun 18

Earnings· Jul 31

Announcements· Jun 19

Technical Analysis· Apr 18

Regulars· Jun 18

Newcomers· Sep 17

Caris Life Sciences SVP Denton sells $238,626 in shares

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)

Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.

Caris Life Sciences vice chairman Brille sells $12.1 million shares

Caris Life Sciences: Diagnostics Growth With Room To Run (NASDAQ:CAI)

Also Discussed

Caris Life Sciences, Inc. Common Stock

Company Information

Location

Caris Life Sciences SVP Denton sells $238,626 in shares

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)

Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.

Caris Life Sciences vice chairman Brille sells $12.1 million shares

Caris Life Sciences: Diagnostics Growth With Room To Run (NASDAQ:CAI)

Also Discussed

Social

Sep 17

Bullish· Jan 2

Bearish· Jun 18

Earnings· Jul 31

Announcements· Jun 19

Technical Analysis· Apr 18

Regulars· Jun 18

Newcomers· Sep 17